Studies using other tracers, such as the anti-CAIX antibody and radioligand [89Zr]Zr-girentuximab or [111In]In-girentuximab, have shown promising results in the imaging of ccRCC. Here, CA9 is linked to nonpapillary renal cell carcinoma.